Mangrove Partners’s Taysha Gene Therapies TSHA Stock Holding History

Mangrove Partners’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,546	Closed	-$113K	–	594
2025 Q4	$113K	Buy	+20,546	New	+$99.8K	0.01%	347

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Mangrove Partners's TSHA Position: Q1 2026 in Review

Mangrove Partners sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 20,546 shares — an estimated $113K sold.

Mangrove Partners first reported a position in TSHA in Q4 2025 and held it in 1 quarter. The position peaked at $113K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Mangrove Partners reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
Mangrove Partners sold 20,546 Taysha Gene Therapies shares in Q1 2026, an estimated $113K.
Mangrove Partners first reported a position in Taysha Gene Therapies in Q4 2025 and held it in 1 quarter.
Mangrove Partners's Taysha Gene Therapies position peaked at $113K in Q4 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.